司美格鲁肽在无糖尿病肥胖患者中减重效果更佳！

Core Insights - The article discusses the efficacy of Semaglutide for weight management in both diabetic and non-diabetic patients, highlighting a significant difference in weight loss outcomes between the two groups [4][5][7]. Summary by Sections Efficacy in Non-Diabetic Patients - Non-diabetic patients using Semaglutide experience an average weight loss of 10.3% to 17.4%, while diabetic patients achieve an average weight loss of only 6.2% [5][9]. - In clinical trials, 86.4% to 88.7% of non-diabetic participants lost at least 5% of their body weight when treated with Semaglutide compared to placebo [9]. Efficacy in Diabetic Patients - The STEP 2 trial, which involved overweight or obese adults with type 2 diabetes, showed that Semaglutide resulted in an average weight loss of 6.2% compared to placebo, with 68.8% of participants losing at least 5% of their body weight [10]. Explanations for Efficacy Differences - The article suggests several potential reasons for the superior efficacy of Semaglutide in non-diabetic patients, including the impact of concomitant medications that promote weight gain in diabetic patients, such as sulfonylureas and insulin [11][13]. - Fear of hypoglycemia in diabetic patients may lead to increased food intake, negatively affecting weight loss outcomes [13]. - Differences in energy expenditure and the longer duration of obesity in diabetic patients may also contribute to the observed disparities in weight loss efficacy [14]. Clinical Trial Overview - The STEP series of clinical trials, which began in June 2018, included approximately 25,000 participants and demonstrated the long-term efficacy and safety of Semaglutide for weight management [7].